Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hipskind
John Hipskind, Research Triangle Park, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20100017918 | ARABIDOPSIS DERIVED PROMOTERS FOR REGULATION OF PLANT EXPRESSION - The invention provides a method to identify a plurality of plant promoters having specified characteristics and promoters identified by the method. Also provided are transgenic plants comprising the genes identified by the methods of the invention. | 01-21-2010 |
John Hipskind, Durham, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090205075 | USE OF PLASTID TRANSIT PEPTIDES DERIVED FROM GLAUCOCYSTOPHYTES - Compositions and methods for targeting polypeptides to plastids are provided. Compositions comprise plastid transit peptides as well as nucleotide sequences encoding such transit peptides and variants thereof. Compositions further comprise DNA constructs comprising a nucleotide sequence encoding the plastid transit peptide operably linked to a nucleotide sequence encoding a polypeptide of interest. These DNA constructs find use in expression and targeting of the polypeptide of interest to a plastid. Compositions also comprise expression cassettes, vectors, transformed plants, transformed plant cells, and stably transformed plant seeds wherein a polypeptide of interest is targeted to a plastid by the plastid transit peptide of the invention. | 08-13-2009 |
Kelly T. Hipskind, Indianapolis, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20110173549 | INTERACTIVE KIOSK SYSTEM AND METHOD - Provided is an interactive kiosk system and method of use. Certain embodiments of a kiosk system may provide users with a wide variety of targeted information, materials and/or services that can be separately administered remotely by multiple unique parties, such as, for example, a plurality of advertisers and one or more managers. In certain embodiments, an interactive kiosk may include videoconferencing capability so that a manager can provide virtual face-to-face assistance to a user. In certain embodiments, an interactive kiosk provides a uniform interface adapted to allow the user to interact with the reservation systems of a plurality of third-parties when the user's identification or payment information is entered only once. | 07-14-2011 |
Philip Arthur Hipskind, New Palastine, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20100324048 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 12-23-2010 |
Philip Arthur Hipskind, Palestine, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20100022560 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS - The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. | 01-28-2010 |
| 20100222339 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists - The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. | 09-02-2010 |
Robert Hipskind, Saint Gely Du Fesc FR
| Patent application number | Description | Published |
|---|---|---|
| 20110150936 | ANTI-TUMORAL CELLS - The present invention relates to the field of preventive or therapeutic anti-tumoral vaccine. More specifically, the present invention relates to live animal tumour cells having a negative MHC-I phenotype, to methods for the production of such MHC-I negative cells, and to their therapeutic use as anti-tumoral agents, particularly via their capacity to activate natural killer (NK) cells. The invention further relates to methods for modulating the level of expression of MHC-I molecules on animal tumour cells, for example by use of specific culture conditions, and/or by use of exogenous agents which directly or indirectly affect levels of MHC-I expression. The invention also concerns activated NK cells and their therapeutic use as anti-tumoral agents. | 06-23-2011 |